Trials / Completed
CompletedNCT04066530
A Study to Evaluate the Efficacy and Safety of AD-203
A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AD-203 in Patients With Acute or Chronic Gastritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 475 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, active-controlled , randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic gastritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-203 | AD-203 administered two times daily for two weeks |
| DRUG | Mucosta tab. | Mucosta tab. administered three times daily for two weeks |
Timeline
- Start date
- 2019-09-23
- Primary completion
- 2020-02-26
- Completion
- 2020-02-26
- First posted
- 2019-08-26
- Last updated
- 2020-12-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04066530. Inclusion in this directory is not an endorsement.